Objective: To investigate ATP7B functional activity and its genetic polymorphisms and postmenopausal ovarian cancer cisplatin-paclitaxel chemotherapy. Correlation of resistance. Methods: One hundred cases of postmenopausal ovarian cancer patients with cisplatin-paclitaxel combined with chemotherapy and 3 cases of postmenopausal ovarian cancer and 3 cases of postmenopausal patients without primary ovarian cancer were collected in our hospital. Ovarian tissue samples were divided into chemotherapy-sensitive group and chemotherapy-resistant group according to drug resistance. RT-PCR and Western Blotting were used to detect the expression of ATP7B mRNA and protein in ovarian cancer patients and patients without primary ovarian cancer. PCR-RFLP was used to detect ATP7B (rs1061472 and rs1801249) sites in postmenopausal ovarian cancer patients. The frequency distribution of genotypes in the sensitive group and the chemoresistance group. The clinical sample data of the two groups were analyzed by independent sample t-test and chi-square test. Results: Compared with the chemotherapy-sensitive group, the mRNA and protein expression levels of ATP7B in the chemotherapy-resistant group were significantly increased. The frequencies of ATP7B rs1061472 and rs1801249 were genotype frequencies in the chemotherapy-sensitive group and ovarian cancer patients in the chemotherapy-resistant group. There was a significant difference in the distribution (P<0.05). Conclusion: The overexpression of ATP7B mRNA in postmenopausal ovarian cancer patients in chemotherapy-resistant group is closely related to the occurrence of cisplatin-paclitaxel combined with chemotherapy. ATP7B rs1061472 and rs1801249 gene polymorphisms were significantly associated with cisplatin-paclitaxel combined chemotherapy resistance in postmenopausal ovarian cancer patients.